16015-07-9

Basic information

• Product Name: 4-isopropylfuran-2-carbaldehyde
• Synonyms: 4-isopropylfuran-2-carbaldehyde;4-(1-methylethyl)-2-Furancarboxaldehyde
• CAS NO: 16015-07-9
• Molecular Formula: C₈H₁₀O₂
• Molecular Weight: 138.1638
• Mol File: 16015-07-9.mol

Chemical Properties

• Boiling Point: 92-95 °C(Press: 13 Torr)
• Appearance: /
• Density: 1.031±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-isopropylfuran-2-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-isopropylfuran-2-carbaldehyde(16015-07-9)
• EPA Substance Registry System: 4-isopropylfuran-2-carbaldehyde(16015-07-9)

Safety Data

• Hazardous Substances Data: 16015-07-9(Hazardous Substances Data)

Usage

Uses

Used in Fragrance Industry:
4-isopropylfuran-2-carbaldehyde is used as a fragrance ingredient for its ability to add a unique and pleasant aroma to perfumes, soaps, and other cosmetic products.
Used in Food Industry:
In the food industry, 4-isopropylfuran-2-carbaldehyde is used as a flavoring agent to enhance the taste and aroma of various food products.

Upstream product

• 98-01-1 furfural 
• 75-29-6 isopropyl chloride 
• 7446-70-0 aluminium trichloride 
• 59413-65-9 (4-isopropyl-furan-2-yl)-methanol 
• 38071-65-7 4-isopropyl-furan-2-carboxylic acid methyl ester 
• 1874-23-3 methyl 5-nitrofuran-2-carboxylate 
• 101384-09-2 4-(1-Methyl-1-nitro-ethyl)-furan-2-carboxylic acid methyl ester 

Downstream Products

• 946113-01-5 C₁₃H₂₁NO₂ 
• 473733-02-7 (R)-1-(4-isopropylfuran-2-yl)propan-1-amine 
• 608537-88-8 C₉H₁₅NO 
• 608537-89-9 C₁₁H₁₉NO 
• 473733-03-8 C₁₂H₂₁NO 

Relevant articles and documents

FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE

This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O?X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists

A novel series of cyclobutenedione centered C(4)-alkyl substituted furanyl analogs was developed as potent CXCR2 and CXCR1 antagonists. Compound 16 exhibits potent inhibitory activities against IL-8 binding to the receptors (CXCR2 Ki = 1 nM, IC50 = 1.3 nM; CXCR1 Ki = 3 nM, IC50 = 7.3 nM), and demonstrates potent inhibition against both Gro-α and IL-8 induced hPMN migration (chemotaxis: CXCR2 IC50 = 0.5 nM, CXCR1 IC50 = 37 nM). In addition, 16 has shown good oral pharmacokinetic profiles in rat, mouse, monkey, and dog.

ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Application of furanyl carbamate cycloadditions toward the synthesis of hexahydroindolinone alkaloids

A convenient synthesis of various substituted hexahydroindolinones has been achieved by an intramolecular Diels-Alder cycloaddition reaction (IMDAF) of furanyl carbamates bearing tethered alkenyl groups. The initially formed [4 + 2]-cycloadduct undergoes nitrogen-assisted ring opening followed by deprotonation of the resulting zwitterion to give the rearranged ketone. The stereochemical outcome of the IMDAF cycloaddition has the sidearm of the tethered alkenyl group oriented syn with respect to the oxygen bridge. A synthetic route to (±)-mesembrane and (±)-crinane was accomplished using this methodology. It was possible to carry out a stereoselective reduction of the initially formed hexahydroindolinone ring to produce the cis-3a-aryl-hydroindole skeleton. A related [4 + 2]-cycloaddition/rearrangement sequence was also used for a formal synthesis of the Chinese ornamental orchid (±)-dendrobine. The tricyclic alkaloid core was formed stereoselectivity from the thermolysis of N-[(2-methyl-2-cyclopentenyl)methyl]-N-(4-isopropyl-furan-2-yl)carbamic acid tert-butyl ester. Kende's advanced intermediate 33 was prepared in seven additional steps by standard transformations, thereby completing a formal synthesis of (±)-dendrobine.